ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Nocardia antimicrobial susceptibility testing by microdilution: evaluation of ready-to-use plate including tedizolid and meropenem.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNocardiosis is a rare but serious infection occurring predominantly in immunocompromised patients. The CLSI microdilution antimicrobial susceptibility testing is recommended for all nocardioses. Ready-to-use plates are available (Sensititre™ RAPMYCOI), but antimicrobials of interest (e.g. tedizolid, meropenem) are lacking. At the request of the French nocardiosis reference medical biology laboratory, a plate including meropenem and tedizolid was produced (Sensititre™ FRNOCAR1).
methodsFRNOCAR1 was compared to RAPMYCOI using 133 clinical Nocardia isolates containing predominantly N. farcinica (23.3%), N. cyriacigeorgica (24.8%), and N. nova complex (21.1%). Acceptability was assessed using the FDA criteria (essential/category agreement; major, and very major error [VME] rates).
resultsAll criteria were respected for 6 antimicrobials; for 5, the upper limit of the VME rate exceeded the criteria, despite a point estimate of 0.0%, due to a lack of resistant strains in the collection. For linezolid, the VME rate could not be calculated due to the absence of linezolid-resistant strains. Tedizolid minimal inhibitory concentration (MIC)50/MIC90 were 2-3 dilutions lower than that of linezolid (0.5/0.5 µg/mL and 2/4 µg/mL, respectively). Imipenem was better than meropenem for N. farcinica; meropenem MIC was at least 2-dilutions lower than that of imipenem for N. gamkensis (8/8), N. gipuzkoensis (2/4), and N. wallacei (4/6).
conclusionFor the antimicrobials common to both plates, the FRNOCAR1 demonstrated good agreement compared with RAPMYCOI. FRNOCAR1 includes tedizolid and meropenem, for which MIC could be reported upon justified request, with a comment indicating that these results are pending further validation.
Indexed as
Identifiers
42400824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.